This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| lung adenocarcinoma | |
|---|---|
| Name | Lung adenocarcinoma |
| Field | Oncology, Pulmonology, Pathology |
lung adenocarcinoma Lung adenocarcinoma is the most common histologic subtype of primary lung cancer and a major cause of cancer mortality worldwide. It arises in the peripheral lung parenchyma and is associated with distinct clinical, radiographic, and molecular features that guide management. Multidisciplinary care often involves specialists from American Cancer Society, National Comprehensive Cancer Network, World Health Organization, American Society of Clinical Oncology, and academic centers such as Mayo Clinic and Memorial Sloan Kettering Cancer Center.
Patients commonly present with cough, dyspnea, chest pain, hemoptysis, or constitutional symptoms such as weight loss and fatigue, often prompting evaluation by clinicians at institutions like Johns Hopkins Hospital, Massachusetts General Hospital, or community hospitals affiliated with Kaiser Permanente. Peripheral tumors may be asymptomatic and discovered incidentally on imaging performed for screening programs endorsed by United States Preventive Services Task Force or surveillance after exposure histories associated with Occupational Safety and Health Administration reports. Symptoms from metastatic spread can include neurologic deficits from brain metastases seen by teams at Cleveland Clinic, bone pain managed by services at MD Anderson Cancer Center, or jaundice from hepatic involvement detected in centers such as Royal Marsden Hospital.
Histologically, tumors show glandular differentiation or mucin production and are classified according to criteria published by organizations like the World Health Organization and reported in monographs from International Agency for Research on Cancer. Immunohistochemical stains (e.g., TTF-1, Napsin A) are interpreted in pathology laboratories following guidelines from the College of American Pathologists and incorporated into reports used by multidisciplinary tumor boards at institutions including Stanford Health Care and University College London Hospitals. Molecular profiling identifies driver alterations in genes such as EGFR, ALK, KRAS, BRAF, ROS1, RET, MET, and NTRK, with testing platforms developed by companies and research groups affiliated with National Institutes of Health, Broad Institute, and Foundation Medicine. Emerging biomarkers like PD-L1 expression and tumor mutational burden inform immunotherapy decisions recommended by panels convened by European Society for Medical Oncology and American Society of Clinical Oncology.
Diagnosis integrates clinical assessment, imaging, and tissue sampling. Chest radiography and computed tomography performed at centers like Royal Brompton Hospital and Guy's and St Thomas' NHS Foundation Trust identify nodules prompting further evaluation with positron emission tomography often available at academic centers such as University of California, San Francisco Medical Center. Tissue acquisition via bronchoscopy, CT-guided percutaneous biopsy, or surgical resection is processed by pathology services following standards from the College of American Pathologists; cytopathology and molecular laboratories collaborate similarly to those at Peter MacCallum Cancer Centre. Liquid biopsy assays commercialized by entities like Guardant Health and research groups at Dana-Farber Cancer Institute can detect circulating tumor DNA to complement tissue testing. Multidisciplinary review and staging consultations are coordinated in tumor boards across institutions such as Memorial Sloan Kettering Cancer Center.
Staging uses the TNM system promulgated by the Union for International Cancer Control and updated by the American Joint Committee on Cancer; staging assessments include CT, PET-CT, and brain MRI as recommended by guidelines from bodies like the National Institute for Health and Care Excellence and NCCN. Mediastinal staging is performed with endobronchial ultrasound or mediastinoscopy at centers such as Royal Brompton Hospital and Mayo Clinic to differentiate nodal stations described in atlases produced by institutions like Johns Hopkins Hospital.
Treatment is multimodal and individualized. Early-stage disease is managed with surgical resection (lobectomy, segmentectomy) performed by thoracic surgery services at Cleveland Clinic and Massachusetts General Hospital with perioperative care informed by anesthesiology units at Mayo Clinic. Adjuvant chemotherapy regimens follow trials conducted by cooperative groups such as Eastern Cooperative Oncology Group and Alliance for Clinical Trials in Oncology. Locally advanced disease may receive concurrent chemoradiation using protocols developed at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Targeted therapies for EGFR mutations, ALK rearrangements, ROS1 fusions, and other drivers use agents approved by regulators such as the Food and Drug Administration and recommended in guidelines from NCCN; examples include tyrosine kinase inhibitors developed through collaborations with pharmaceutical companies and academic centers. Immune checkpoint inhibitors targeting PD-1/PD-L1 have become standard for many patients based on trials led by consortia including European Organisation for Research and Treatment of Cancer and SWOG. Palliative care and supportive oncology services integrate models promoted by World Health Organization and hospices affiliated with university centers.
Prognosis depends on stage, performance status, and molecular profile; data aggregated by registries such as the Surveillance, Epidemiology, and End Results Program and studies from International Association for the Study of Lung Cancer inform survival estimates. Patients with actionable mutations treated with targeted agents may experience prolonged progression-free survival reported in trials conducted at centers like Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center, whereas advanced disease without targets has outcomes improved by immunotherapy studies from groups including KEYNOTE investigators and cooperative oncology networks.
Epidemiology is documented by agencies such as the World Health Organization, Centers for Disease Control and Prevention, and national cancer registries including the National Cancer Registry systems in multiple countries. Smoking remains a principal risk factor identified in historical cohorts from Framingham Heart Study-era research, but increasing proportions occur in never-smokers and are linked to environmental exposures such as radon, asbestos, and air pollution studied by groups including Environmental Protection Agency and International Agency for Research on Cancer. Demographic patterns vary by region with notable incidence differences reported between populations in United States, China, Japan, and European Union member states.
Category:Thoracic oncology